AI Heads to Washington
To help you understand the trends surrounding AI and other new technologies and what we expect to happen in the future, our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts. (Get a free issue of The Kiplinger Letter or subscribe).
» Read more about: AI Heads to Washington »
Read MoreThese 15 Funds Were the Worst Performing of the Past Decade—Is One in Your Portfolio?
The past decade has seen one of the strongest bull markets in history, with the S&P 500 index posting a 10-year return of 182.9% through February 2025. Yet a select club of exchange-traded funds (ETFs) no one wants to join managed to defy a broadly rising market and destroy billions in shareholder value.
Read MoreTrump tariffs live updates: US moves to levy Chinese ships as Trump softens rhetoric
President Trump offered an update on negotiations with the US’s trading partners during the 90-day pause on his additional reciprocal tariffs.
“We’re doing very well with negotiations, I think, with all countries,” Trump said to reporters after meeting with Italian Prime Minister Giorgia Meloni on Thursday. “We have a lot of countries that want to make a deal.
Read MoreGold ETFs vs physical gold: Which gives better returns over 10 to 15 years?
Representative image
Physical gold—whether in the form of jewellery, coins, or bars—has long been considered a safe-haven asset by Indian households. Its cultural appeal, use in ceremonies, and psychological assurance of tangible ownership continue to make it a preferred choice for many. Over the past 10 to 15 years,
» Read more about: Gold ETFs vs physical gold: Which gives better returns over 10 to 15 years? »
Read MoreDow Jones falls more than 500 points, fueled by UnitedHealth tumble
Stock market turmoil continued Thursday with the Dow Jones closing in the red. The drop comes as investors weigh progress in trade negotiations with Japan and navigate general uncertainty over the Trump administration’s tariff plan. Notably, UnitedHealth shares fell after the company announced a cut to its annual profit forecast, citing expectations of high medical costs for the rest of the year.
» Read more about: Dow Jones falls more than 500 points, fueled by UnitedHealth tumble »
Read MoreThe Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
1 Cash Cow with Massive Upside
CVS Health (NYSE:CVS) share price declined by over 23% over the past twelve months. Hurting shareholders was the recent leadership transition from CEO Karen Lynch to David Joyner, a shift that brought uncertainty to the company’s direction as investors questioned the company’s stability while facing ongoing challenges.
» Read more about: 1 Cash Cow with Massive Upside »
Read MoreThe Spotlight
Will Ford’s EV Gamble Pay Off?
As we race towards the end of 2024, a full 17 million electric vehicles are projected to be sold, which if realized will translate to a whopping 1 in 5 of all car sales.
With demand for EV’s as strong as ever and competition from Tesla and China’s BYD stiffening, what does the future hold for Ford and its EV strategy?